third, the surging global epidemic of obesity (over 890 million adults globally in 2024) and diabetes (537 million currently, projected 783 million by 2045) creating structural demand for semaglutide therapies
Slip and Fall / Premises Liability: When property owners fail to keep places safe, people get hurt
[31] The takeaway is vigilance: any GLP-1 user with diabetes especially on combined therapy with SGLT2 inhibitors, who presents with persistent vomiting or reduced oral intake deserves consideration for EDKA
The right dose, the right support, and a structure that does not feel overwhelming
Metabolic Health & Anti-Inflammatory Benefits Dosage: 35 mg per week (SC or IV) Cycle: 4-week cycle, repeated every 612 months Administration: Best taken while following a low-inflammatory diet (paleo, keto, or fasting protocols) Stacking: With Berberine or AICAR for metabolic regulation With Thymosin Alpha-1 (TA-1) for immune modulation Expected Benefits: Reduced chronic inflammation and oxidative stress Improved insulin sensitivity and glucose metabolism Enhanced mitochondrial function and energy levels Further reading FOXO4-DRI belongs to a class of compounds known as senolytics, which are designed to target and remove senescent cells
